Search

Incyte Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

120.01 2.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

115.47

Max

120.39

Pagrindiniai rodikliai

By Trading Economics

Pajamos

282M

586M

Pardavimai

401M

1.7B

P/E

Sektoriaus vid.

15.087

68.51

Pelnas, tenkantis vienai akcijai

2.8

Pelno marža

34.982

Darbuotojai

2,844

EBITDA

384M

752M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+9.77% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

257M

24B

Ankstesnė atidarymo kaina

117.75

Ankstesnė uždarymo kaina

120.01

Naujienos nuotaikos

By Acuity

45%

55%

153 / 340 reitingas Healthcare

Incyte Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-06 19:44; UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

2026-08-05 19:56; UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

2026-08-04 19:46; UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

2026-08-03 23:56; UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

2026-07-31 22:21; UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026-07-30 23:56; UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

2026-07-29 22:51; UTC

Event

Incyte Corp shares are higher after the European Commission approved Opzelura® for moderate atopic dermatitis treatment. Market conditions are also advancing in after-market trading.

2026-07-28 23:02; UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline influenced by concerns over technology stocks and geopolitical tensions.

2026-07-27 23:02; UTC

Incyte Corp shares are lower in after-market hours, following a decline earlier in the session amid broader market sentiment influenced by falling crude oil prices.

2026-07-24 21:01; UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment was affected by a sharp Nasdaq decline.

2026-07-22 20:04; UTC

Incyte Corp's shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average and near the upper end of its one-month range.

2026-07-21 16:36; UTC

Social Media
News

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to gains in Incyte shares during Tuesday's session.

2026-07-20 21:56; UTC

Incyte Corp shares are lower in after-market hours following a volatile session, despite trading above the 20-day moving average and near a one-month high.

2026-07-17 23:16; UTC

Incyte Corp shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the movement.

2026-07-16 23:06; UTC

Incyte Corp shares are trading lower in after-market hours amid a broader market decline, influenced by rising interest rates and geopolitical tensions.

2026-07-15 19:16; UTC

News

Incyte Corp remains elevated above its 20-day moving average, recently surpassing Weyerhaeuser to become the 400th largest company in the S&P 500.

2026-07-13 16:21; UTC

News
Event

Incyte Corp shares are lower amid concerns over revenue guidance despite positive Phase 1/2 data for latarcibart presented at ISTH 2026 Congress.

2026-07-10 20:06; UTC

Incyte Corp's shares are lower today, influenced by declines in the Biotechnology sub-sector. The stock peaked early before steadily declining throughout the session.

2026-07-09 23:56; UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

2026-07-08 20:04; UTC

Incyte Corp shares are lower as biotechnology stocks face pressure. The broader sector's significant losses have impacted Incyte's performance today.

2026-07-07 23:06; UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline. No specific company news has been identified to influence the price.

2026-07-06 23:01; UTC

Incyte Corp shares are higher in after-market trading, approaching the upper end of their one-month trading range. No specific news was identified for this movement.

2026-07-03 00:01; UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market conditions may be influencing investor sentiment.

2026-07-02 23:01; UTC

Incyte Corp shares declined in after-market hours amid notable volatility, contrasting with three consecutive sessions of gains. No specific news was identified for the move.

2026-07-01 21:01; UTC

Incyte Corp shares are higher in after-market trading, reflecting a notable increase as they approach the upper end of their one-month range.

2026-06-30 23:01; UTC

Incyte Corp shares are higher in after-market trading, maintaining an upward trend despite broader market declines, particularly in the tech sector.

2026-06-29 23:16; UTC

Event

Incyte Corp shares are higher in after-market trading following positive results from the Phase 2b trial of EVO756 for chronic spontaneous urticaria.

2026-06-26 23:51; UTC

Event

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

2026-06-25 23:51; UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

2026-06-24 20:02; UTC

News
Social Media

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

Akcijų palyginimas

Kainos pokytis

Incyte Corp Prognozė

Kainos tikslas

By TipRanks

9.77% į viršų

12 mėnesių prognozė

Vidutinis 129.94 USD  9.77%

Aukščiausias 155 USD

Žemiausias 109 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Incyte Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

20 ratings

10

Pirkti

10

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

153 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat